文献速递颈动脉与弓上血管

颈动脉支架术后严重持续性低血压的多因素分析

Multivariable Analysis of Patients With Severe Persistent Postprocedural Hypotension After Carotid Artery Stenting.
PubMed 文献 · J Endovasc Ther · 2019-08-21

该回顾性多中心研究分析了146例患者共160次颈动脉支架术,发现术后严重持续性低血压发生率为24.7%(36例患者)。严重病变钙化和对比剂用量与低血压相关,不同脑保护装置和支架类型间风险存在差异。

要点

  • 颈动脉支架术后严重持续性低血压发生率为24.7%,延长ICU和住院时间。
  • 严重病变钙化(OR 6.28)和对比剂用量(OR 1.02)与低血压独立相关。
  • Precise支架和对比剂用量是多变量模型中的显著预测因素。

核心结论

  • 手术复杂性和支架类型可能在颈动脉支架术后低血压发生中起作用。

研究设计与样本

  • 回顾性分析3个血管中心146例患者(平均年龄72.8岁,104例男性)共160次颈动脉支架术,采用标准化方案。

主要发现

  • 36例(24.7%)患者发生术后低血压,涉及37次(23.1%)手术。
  • 发生低血压的患者ICU和住院时间显著更长(p<0.001)。
  • 严重病变钙化与低血压相关(OR 6.28,95%CI 1.81-21.98,p=0.004)。
  • 对比剂用量与低血压相关(OR 1.02,95%CI 1.01-1.02,p<0.001)。
  • Angioguard与Emboshield NAV6装置间低血压风险差异有统计学意义(OR 4.22,95%CI 1.38-13.33,p=0.012)。

关键数值与推荐

  • 术后低血压定义为收缩压较基线下降>40 mmHg或收缩压<90 mmHg持续>1小时。
  • Precise与Xact支架比较:OR 6,95%CI 2.08-17.6,p=0.001。
  • Bootstrapped多变量模型确定Precise支架和对比剂用量为持续性术后低血压的显著预测因素。

临床怎么用

  • 对于严重钙化病变或使用较多对比剂的患者,术后应加强血压监测。
  • 选择支架和脑保护装置时需考虑术后低血压风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose: To assess the incidence and predictors of severe, persistent postprocedural hypotension (PPH) after carotid artery stenting (CAS). Materials and Methods: A total of 146 patients (mean age 72.8 years; 104 men) who underwent 160 CAS procedures using a standardized protocol at 3 vascular centers were retrospectively analyzed. The primary endpoint was postprocedural hypotension, defined as a reduction in systolic blood pressure (SBP) >40 mm Hg from baseline or an SBP of <90 mm Hg sustained for >1 hour after CAS. Potential prognostic factors for postprocedural hypotension were identified and subjected to logistic regression analyses; outcomes are presented as the odds ratios (ORs) with 95% confidence intervals (CIs). Results: PPH developed in 36 (24.7%) patients after 37 (23.1%) CAS procedures. These patients had significantly longer intensive care unit and hospital stays than those who did not develop hypotension (p<0.001). PPH was associated with severe lesion calcification (OR 6.28, 95% CI 1.81 to 21.98, p=0.004) and contrast volume (OR 1.02, 95% CI 1.01 to 1.02, p<0.001). A 4-fold increase in the risk of PPH (OR 4.22, 95% CI 1.38 to 13.33, p=0.012) was found between the embolic protection device most associated with PPH (Angioguard) and the device least associated with PPH (Emboshield NAV6). A similar trend was also observed for the Precise vs Xact stents (OR 6, 95% CI 2.08 to 17.6, p=0.001). Bootstrapped multivariable modeling identified the Precise stent and contrast volume as significant predictors of persistent postprocedural hypotension. Further investigation of the contrast volume revealed associations with sex, severe calcification, arch type, previous coronary artery bypass surgery, and primary stenting, suggesting that the contrast volume reflects the complexity of the procedure. Conclusion: The complexity of the procedure and type of stent may play a role in the development of postprocedural hypotension after CAS.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Oshin O, Varcoe R, Wong J, et al. Multivariable Analysis of Patients With Severe Persistent Postprocedural Hypotension After Carotid Artery Stenting. J Endovasc Ther. 2019. PMID: 31431153. doi:10.1177/1526602819869929

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。